At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
IGF-1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
IGF-1 Therapy and Muscle Function in Duchenne Muscular Dystrophy
Children's Hospital Medical Center, Cincinnati·interventional·Posted Sep 23, 2010·Updated Jan 20, 2021
In Brief
A Phase 2 clinical trial evaluating IGF-1 for Duchenne Muscular Dystrophy. Completed, enrolled 44 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle function in Duchenne Muscular Dystrophy (DMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDuchenne Muscular Dystrophy
CountriesUnited States
CollaboratorsIpsen, Charley's Fund
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartNov 2010
Primary CompletionOct 2012
Study CompletionJun 2013
TodayJul 2026
First PostedSep 23, 2010
Enrollment StartNov 1, 2010
Primary CompletionOct 1, 2012
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 15.8 years ago
Interventions
IGF-1drug
IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.